下一代免疫疗法:为肺癌点燃新的希望
Molly S C Li1, Andrew L S Chan1, Kevin K S Mok2
1State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Therapeutic advances in medical oncology
|December 9, 2024
概括
免疫疗法,特别是抗编程死亡蛋白 (PD-L) 已经改变了癌症护理,但在非小细胞肺癌 (NSCLC) 中,耐药性很常见. 新型免疫疗法在克服耐药性和改善结果方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 免疫疗法,特别是抗编程死亡 (配体) 蛋白 (PD-L) 1疗法,已经彻底改变了癌症治疗,在晚期癌症中提供了持久的反应和长期生存.
- 抗PD-(L) 1药物在非小细胞肺癌 (NSCLC) 中是标准的,无论其组织学或阶段如何.
- 然而,显著大多数晚期NSCLC患者对抗PD-(L) 1疗法产生耐药性,导致预后不佳.
研究的目的:
- 审查非小细胞肺癌 (NSCLC) 抗PD-(L) 1疗法的耐药性机制.
- 讨论可能克服这些抵抗机制的新型免疫治疗方式.
- 为这些新兴疗法的未来临床整合提供视角.
主要方法:
- 文献综述侧重于NSCLC中的抗PD-L) 1耐药机制.
- 讨论新兴的免疫疗法,包括组合疗法,双特异抗体,癌症疫苗和细胞疗法.
- 分析早期临床数据和潜在的协同效应.
主要成果:
- 在NSCLC中抗PD-(L) 1治疗的耐药性是复杂的,涉及癌症免疫循环中的缺陷,如抗原呈现受损,T细胞原始化,联合抑制信号,免疫细胞透和免疫抑制瘤微环境.
- 新一代免疫疗法,包括新的组合,双特异性抗体,癌症疫苗和细胞疗法正在开发中,以解决这些抵抗机制.
- 这些新的方法在NSCLC中显示出有前途的早期临床数据.
结论:
- 了解抗PD-(L) 1治疗的多面性耐药机制对于开发NSCLC有效治疗至关重要.
- 新型免疫治疗策略具有恢复抗瘤免疫力和克服抵抗力的巨大潜力.
- 需要进一步的研究和临床验证,才能将这些有前途的新型免疫疗法转化为NSCLC患者的标准临床实践.
相关概念视频
01:27Tumor Immunotherapy
476
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
476
01:30Cancer Vaccines
338
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
338
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K